Royalty Pharma plc · Drugmakers

RPRX

Low riskNext report: Around Nov 4 (est.)

View price ↗

The short version

A profitable company with growing sales. Institutions are adding.

Going well

Sales up 17% in the latest quarter vs a year ago
Profitable every year for 8 years
Brings in more cash than it spends

Watch out for

Share count growing 8.8% a year

Money moves

Insiders sold $474K in the last 30 days, all through pre-planned sales
Institutions added 2.7% to their holdings in the quarter ending June 2026 (384 bought, 218 sold)
Held by Ray Dalio (Bridgewater)

Facts from SEC filings, not a recommendation.

What the price means

Price as of Oct 26

$64.77+1.5% that day

Company value: $25.1B; Share price times all shares
Price vs profit (P/E): 34.5x; You pay about $34 for each $1 of yearly profit
Price vs sales: 9.9x; Company value is 9.9 times a year of sales
Cash vs value: 3%; Cash as a share of company value
Debt vs value: 36%; Debt as a share of company value

From RPRX's last IEX trade and its SEC filings (profits and sales over the last four quarters). A starting point for research, not a verdict.

The business over time

Last 12 quarters, from SEC filings

Sales, Jun '26

$674.1M+16% vs a year earlier

Sep '23Tap a barJun '26

Last 12 months: $2.5B, up 10% from the 12 months before. Over 5 years, sales grew about 2.3% a year.

What the price assumes

Your guesses, our math

Move the sliders to your own view of RPRX. Starting points are the company's recent numbers.

Sales growth+10% a yearRecently: +10% a yearProfit margin32%Last 12 months: 32.1%P/E at the end34xToday: 34.5x. Many steady companies trade at 12x to 25xShare count change+10% a yearBelow zero means buybacks; above zero means new shares (dilution)

Sales in 5 years$4.1B

Profit in 5 years$1.3B

Price these guesses point to$71.09+9.8% vs $64.77 todayAbout +1.9% a year, before dividends

What today's price needs: with a 32% margin and a 34x P/E, sales would have to grow about 8.0% a year for 5 years just to match today's price.

Simple math on your guesses, not a forecast or a price target. Real results depend on many things these sliders leave out.

Price

Price chart by TradingView.

Business quality

The checklist Warren Buffett-style investors use. Annual numbers for 2025.

3/4Mixed

PassNet margin 10%+Keeps at least 10 cents of profit from each dollar of sales.32.4%
PassProfitable every yearSteady profits, not one good year.8 of 8 years
PassFree cash flow positiveBrings in more cash than it spends to run and grow.$2.5B
MissShare count not growingNot diluting owners. Falling means buybacks.+28.9% in 3 years

Revenue: $2.4B; +5.1% vs prior year
5-year growth: +2.3%/yr; revenue, per year
Total debt: $9.0B
Current ratio: 2.40x; short-term assets / bills due

From annual reports filed with the SEC. Not in this company's SEC data, so not scored: return on equity 15%+, debt under half of equity, gross margin 40%+. A checklist is a starting point for research, not a verdict.

Latest quarter

Quarter ended Jun 30, 2026

Reported Aug 5

Revenue: $674.1M; +16.5% YoY
EPS: $0.04; vs $0.07
Op. margin: 19.7%; -16.6 pts
Free cash flow: $728.5M
Share count: -1.0%; vs a year ago

Insider rating

Last 90 days

46Mixed

Pre-planned sales of $474K (weaker signal)

50 is neutral. Buying by more insiders, top executives and bigger stakes raises it. Selling lowers it; pre-planned sales count less.

Weekly insider trend

13 weeks agoBoughtSoldThis week

Filing buzz

Last 7 days vs normal

0/ 100

This week: 0
Normal week: 1.6
vs normal: 0.0x

SEC filings of any kind. 50 means a normal week.

Institutional ownership

Accumulating+2.7%

Institutions added 2.7% to their holdings. 384 bought, 218 sold.

Shares held by institutions366.6M

Sep '24Jun '26

Safety check

From SEC filings

Share count growthYearly rate, last 3 years

+8.8%

Cash runwayAt last year's cash burn

Cash flow positive

Debt to equityLatest balance sheet: debt compared with what owners have

0.9x · $9.0B debt

Shares outstandingLatest reported

388M

Earnings reports

Last 12

Next reportAround Nov 4 (est.)Estimated from the same quarter last year

Results filedAug 5
Results filedMay 6
Results filedFeb 11
Results filedNov 5, 2025
Results filedAug 6, 2025

Flags and big holders

Offerings 6 months, flags 12 months, holders 90 days

5%+ holder update (active)Aug 17 · View filing ↗Activist

Insider trades

Open-market buys and sells, last 90 days

Bought$00 insiders

Sold$474K1 insider, 2 pre-planned

Insider	Trade	Shares	Avg price	Value	Owns after	Date
Marshall UristEVP, Research & Investments	Sell	4K	$57.10	$236K	0	Oct 5Filing ↗
Sold entire stake Pre-planned sale (10b5-1) Filed same day
Marshall UristEVP, Research & Investments	Sell	4K	$57.88	$239K	4K	Sep 28Filing ↗
-50% of their holdings Pre-planned sale (10b5-1) Filed 2 days after